PKMYT1 Antibody

Total Page：16

File Type：pdf, Size：1020Kb

Product Datasheet PKMYT1 Antibody Catalog No: #37829 Orders: [email protected] Description Support: [email protected] Product Name PKMYT1 Antibody Host Species Rabbit Clonality Polyclonal Purification Antigen affinity purification. Applications WB IHC Species Reactivity Hu Ms Specificity The antibody detects endogenous levels of total PKMYT1 protein. Immunogen Type Peptide Immunogen Description Synthetic peptide corresponding to a region derived from internal residues of human protein kinase, membrane associated tyrosine/threonine 1 Target Name PKMYT1 Other Names MYT1; PPP1R126 Accession No. Swiss-Prot#: Q99640NCBI Gene ID: 9088Gene Accssion: NP_004194 /Q99640 SDS-PAGE MW 55kd Concentration 0.8mg/ml Formulation Rabbit IgG in pH7.4 PBS, 0.05% NaN3, 40% Glycerol. Storage Store at -20°C Application Details Western blotting: 1:200-1:1000 Immunohistochemistry: 1:25-1:50 Images Gel: 8%SDS-PAGELysate: 40 ΞΌgLane: A375 cell lysatePrimary antibody: PKMYT1 Antibody at dilution 1/200Secondary antibody: Goat anti rabbit IgG at 1/5000 dilutionExposure time: 5 minutes Address: 8400 Baltimore Ave., Suite 302, College Park, MD 20740, USA http://www.sabbiotech.com 1 The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using PKMYT1 Antibody at dilution 1/35. (Original magnification: Γ200). Background This gene encodes a member of the serine/threonine protein kinase family. The encoded protein is a membrane-associated kinase that negatively regulates the G2/M transition of the cell cycle by phosphorylating and inactivating cyclin-dependent kinase 1. The activity of the encoded protein is regulated by polo-like kinase 1. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. Note: This product is for in vitro research use only and is not intended for use in humans or animals. Address: 8400 Baltimore Ave., Suite 302, College Park, MD 20740, USA http://www.sabbiotech.com 2.

Copy Link

Recommended publications

Systematic Screening for Potential Therapeutic Targets in Osteosarcoma Through a Kinome-Wide CRISPR-Cas9 Library
Cancer Biol Med 2020. doi: 10.20892/j.issn.2095-3941.2020.0162 ORIGINAL ARTICLE Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library Yuanzhong Wu*, Liwen Zhou*, Zifeng Wang, Xin Wang, Ruhua Zhang, Lisi Zheng, Tiebang Kang Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China ABSTRACT Objective: Osteosarcoma is the most common primary malignant bone tumor. However, the survival of patients with osteosarcoma has remained unchanged during the past 30 years, owing to a lack of efficient therapeutic targets. Methods: We constructed a kinome-targeting CRISPR-Cas9 library containing 507 kinases and 100 nontargeting controls and screened the potential kinase targets in osteosarcoma. The CRISPR screening sequencing data were analyzed with the Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) Python package. The functional data were applied in the 143B cell line through lenti-CRISPR-mediated gene knockout. The clinical significance of kinases in the survival of patients with osteosarcoma was analyzed in the R2: Genomics Analysis and Visualization Platform. Results: We identified 53 potential kinase targets in osteosarcoma. Among these targets, we analyzed 3 kinases, TRRAP, PKMYT1, and TP53RK, to validate their oncogenic functions in osteosarcoma. PKMYT1 and TP53RK showed higher expression in osteosarcoma than in normal bone tissue, whereas TRRAP showed no significant difference. High expression of all 3 kinases was associated with relatively poor prognosis in patients with osteosarcoma. Conclusions: Our results not only offer potential therapeutic kinase targets in osteosarcoma but also provide a paradigm for functional genetic screening by using a CRISPR-Cas9 library, including target design, library construction, screening workflow, data analysis, and functional validation.
[Show full text]
The Combination of the PARP Inhibitor Olaparib and the Wee1 Inhibitor AZD1775 As a New Therapeutic Option for Small Cell Lung Cancer
Author Manuscript Published OnlineFirst on June 25, 2018; DOI: 10.1158/1078-0432.CCR-17-2805 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer Alice Lallo1,*, Kristopher K Frese1,*, Christopher J Morrow1, Robert Sloane1, Sakshi Gulati1, Maximillian W Schenk1, Francesca Trapani1, Nicole Simms1, Melanie Galvin1, Stewart Brown1, Cassandra L Hodgkinson1, Lynsey Priest1, Adina Hughes4, Zhongwu Lai5, Elaine Cadogan4, Garima Khandelwal3, Kathryn L Simpson1, Crispin Miller3, Fiona Blackhall2, Mark J O’Connor4,#, and Caroline Dive1,# 1 Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, M20 4BX, UK. 2 Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom. Christie NHS Foundation Trust, Manchester, M20 4BX, UK. 3 RNA Biology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, M20 4BX, UK. 4 Oncology Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Cambridge, CB2 0RE, UK. 5 Oncology Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Waltham, 02451, USA. *These authors contributed equally to this work Running title: PARP and Wee1 inhibition in patient-derived models of SCLC C. Dive receives funding from the Cancer Research UK Manchester Institute core (C5759/A27412), the Cancer Research UK Manchester
[Show full text]
Bioinformatics-Based Screening of Key Genes for Transformation of Liver
Jiang et al. J Transl Med (2020) 18:40 https://doi.org/10.1186/s12967-020-02229-8 Journal of Translational Medicine RESEARCH Open Access Bioinformatics-based screening of key genes for transformation of liver cirrhosis to hepatocellular carcinoma Chen Hao Jiang1,2, Xin Yuan1,2, Jiang Fen Li1,2, Yu Fang Xie1,2, An Zhi Zhang1,2, Xue Li Wang1,2, Lan Yang1,2, Chun Xia Liu1,2, Wei Hua Liang1,2, Li Juan Pang1,2, Hong Zou1,2, Xiao Bin Cui1,2, Xi Hua Shen1,2, Yan Qi1,2, Jin Fang Jiang1,2, Wen Yi Gu4, Feng Li1,2,3 and Jian Ming Hu1,2* Abstract Background: Hepatocellular carcinoma (HCC) is the most common type of liver tumour, and is closely related to liver cirrhosis. Previous studies have focussed on the pathogenesis of liver cirrhosis developing into HCC, but the molecular mechanism remains unclear. The aims of the present study were to identify key genes related to the transformation of cirrhosis into HCC, and explore the associated molecular mechanisms. Methods: GSE89377, GSE17548, GSE63898 and GSE54236 mRNA microarray datasets from Gene Expression Omni- bus (GEO) were analysed to obtain diferentially expressed genes (DEGs) between HCC and liver cirrhosis tissues, and network analysis of protein–protein interactions (PPIs) was carried out. String and Cytoscape were used to analyse modules and identify hub genes, Kaplan–Meier Plotter and Oncomine databases were used to explore relationships between hub genes and disease occurrence, development and prognosis of HCC, and the molecular mechanism of the main hub gene was probed using Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway analysis.
[Show full text]
NIH Public Access Author Manuscript J Theor Biol
NIH Public Access Author Manuscript J Theor Biol. Author manuscript; available in PMC 2014 March 07. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: J Theor Biol. 2013 March 7; 320: . doi:10.1016/j.jtbi.2012.12.011. A predictive mathematical model of the DNA damage G2 checkpoint Kevin J. Kesselera, Michael L. Blinovb, Timothy C. Elstonc, William K. Kaufmanna, and Dennis A. Simpsona,* aDepartment of Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, Center for Environmental Health and Susceptibility, University of North Carolina at Chapel Hill, NC 27599-7255, USA bCenter for Cell Analysis and Modeling, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-1507, USA cDepartment of Pharmacology, University of North Carolina at Chapel Hill,Chapel Hill, NC 27599-7260, USA Abstract A predictive mathematical model of the transition from the G2 phase in the cell cycle to mitosis (M) was constructed from the known interactions of the proteins that are thought to play significant roles in the G2 to M transition as well as the DNA damage- induced G2 checkpoint. The model simulates the accumulation of active cyclin B1/Cdk1 (MPF) complexes in the nucleus to activate mitosis, the inhibition of this process by DNA damage, and transport of component proteins between cytoplasm and nucleus. Interactions in the model are based on activities of individual phospho-epitopes and binding sites of proteins involved in G2/M. Because tracking phosphoforms leads to combinatorial explosion, we employ a rule-based approach using the BioNetGen software. The model was used to determine the effects of depletion or over-expression of selected proteins involved in the regulation of the G2 to M transition in the presence and absence of DNA damage.
[Show full text]
Small-Molecule Binding Sites to Explore New Targets in the Cancer Proteome
Electronic Supplementary Material (ESI) for Molecular BioSystems. This journal is © The Royal Society of Chemistry 2016 Small-molecule binding sites to explore new targets in the cancer proteome David Xu, Shadia I. Jalal, George W. Sledge Jr., and Samy O. Meroueh* Supplementary Text Druggable Binding Sites across all 10 Diseases. Using the previously established cutoffs, we identified genes that were overexpressed across multiple cancer types and featured druggable binding sites. We ranked these genes based on the total number of tumors that overexpressed the gene (Fig. S1). Using a simple PubMed query, we then counted the number of articles in which either the gene symbol or gene name was co-mentioned with the term ‘cancer’. Most of the most frequently occurring differentially-expressed genes correspond to proteins of well- established cancer targets. Among them are matrix metalloproteinases (MMPs), including MMP1, MMP9, and MMP12, which are implicated in tumor invasion and metastasis (1). There are several protein kinases, including TTK, AURKA, AURKB, and PLK1, that are involved in cell signaling and well-established oncology targets (2). Some genes among this list that have not been extensively studied nor targeted in cancer. These include the serine/threonine kinase PKMYT1 (MYT1) is a regulator of G2/M transition in the cell cycle, but lacks focused small molecule inhibitors that specifically target the kinase. Recent efforts in developing small molecule inhibitors involve repurposing of available kinase inhibitors to specifically target the kinase (3). A subunit of the GINS complex GINS2 (PSF2) is involved in cell proliferation and survival in cancer cell lines (4,5).
[Show full text]
Ser 15 of WEE1B Is a Potential PKA Phosphorylation Target in G2/M Transition in One-Cell Stage Mouse Embryos
MOLECULAR MEDICINE REPORTS 7: 1929-1937, 2013 Ser 15 of WEE1B is a potential PKA phosphorylation target in G2/M transition in one-cell stage mouse embryos CHAO LIU1,2, YANCHUN LIU1, YANG LIU2, DIDI WU1, ZHIDONG LUAN2, ENHUA WANG3 and BINGZHI YU1,3 1Department of Biochemistry and Molecular Biology, China Medical University, Shenyang; 2Department of Developmental Biology, Liaoning Medical University, Jinzhou; 3Institute of Pathology and Pathopysiology, China Medical University, Shenyang, Liaoning, P.R. China Received December 17, 2012; Accepted March 28, 2013 DOI: 10.3892/mmr.2013.1437 Abstract. The WEE1 kinase family has been shown to be the Introduction major kinase family responsible for phosphorylating Tyr 15 on cyclin-dependent kinase 1 (CDK1). WEE1 homolog 2 (WEE2, M phase-promoting factor (MPF) is a universal regulator of M also known as WEE1B) was first identified in Xenopus laevis phase in the eukaryotic cell cycle (1,2). Its activation induces and more recently in humans and mice, and is responsible for entry into M phase and its subsequent inactivation is necessary phosphorylating the CDK1 inhibitory site and maintaining to exit from M phase. The activity of MPF in higher eukary- meiotic arrest in oocytes. However, the mechanism by which otic cells is primarily regulated by the formation of a complex WEE1B is regulated in one-cell stage mouse embryos remains between the catalytic cyclin-dependent kinase 1 (CDK1, to be elucidated. In the present study, we examined the role previously known as CDC2) subunit and the regulatory of WEE1B-Ser 15 in G2/M transition of one-cell stage mouse CCNB1 (previously known as cyclin B) subunit, and further embryos.
[Show full text]
Biomarkers, Master Regulators and Genomic Fabric Remodeling in a Case of Papillary Thyroid Carcinoma
G C A T T A C G G C A T genes Article Biomarkers, Master Regulators and Genomic Fabric Remodeling in a Case of Papillary Thyroid Carcinoma Dumitru A. Iacobas Personalized Genomics Laboratory, CRI Center for Computational Systems Biology, Roy G Perry College of Engineering, Prairie View A&M University, Prairie View, TX 77446, USA; [email protected]; Tel.: +1-936-261-9926 Received: 1 August 2020; Accepted: 1 September 2020; Published: 2 September 2020 Abstract: Publicly available (own) transcriptomic data have been analyzed to quantify the alteration in functional pathways in thyroid cancer, establish the gene hierarchy, identify potential gene targets and predict the effects of their manipulation. The expression data have been generated by profiling one case of papillary thyroid carcinoma (PTC) and genetically manipulated BCPAP (papillary) and 8505C (anaplastic) human thyroid cancer cell lines. The study used the genomic fabric paradigm that considers the transcriptome as a multi-dimensional mathematical object based on the three independent characteristics that can be derived for each gene from the expression data. We found remarkable remodeling of the thyroid hormone synthesis, cell cycle, oxidative phosphorylation and apoptosis pathways. Serine peptidase inhibitor, Kunitz type, 2 (SPINT2) was identified as the Gene Master Regulator of the investigated PTC. The substantial increase in the expression synergism of SPINT2 with apoptosis genes in the cancer nodule with respect to the surrounding normal tissue (NOR) suggests that SPINT2 experimental overexpression may force the PTC cells into apoptosis with a negligible effect on the NOR cells. The predictive value of the expression coordination for the expression regulation was validated with data from 8505C and BCPAP cell lines before and after lentiviral transfection with DDX19B.
[Show full text]
Activation of Diverse Signalling Pathways by Oncogenic PIK3CA Mutations
ARTICLE Received 14 Feb 2014 | Accepted 12 Aug 2014 | Published 23 Sep 2014 DOI: 10.1038/ncomms5961 Activation of diverse signalling pathways by oncogenic PIK3CA mutations Xinyan Wu1, Santosh Renuse2,3, Nandini A. Sahasrabuddhe2,4, Muhammad Saddiq Zahari1, Raghothama Chaerkady1, Min-Sik Kim1, Raja S. Nirujogi2, Morassa Mohseni1, Praveen Kumar2,4, Rajesh Raju2, Jun Zhong1, Jian Yang5, Johnathan Neiswinger6, Jun-Seop Jeong6, Robert Newman6, Maureen A. Powers7, Babu Lal Somani2, Edward Gabrielson8, Saraswati Sukumar9, Vered Stearns9, Jiang Qian10, Heng Zhu6, Bert Vogelstein5, Ben Ho Park9 & Akhilesh Pandey1,8,9 The PIK3CA gene is frequently mutated in human cancers. Here we carry out a SILAC-based quantitative phosphoproteomic analysis using isogenic knockin cell lines containing ‘driver’ oncogenic mutations of PIK3CA to dissect the signalling mechanisms responsible for oncogenic phenotypes induced by mutant PIK3CA. From 8,075 unique phosphopeptides identiﬁed, we observe that aberrant activation of PI3K pathway leads to increased phosphorylation of a surprisingly wide variety of kinases and downstream signalling networks. Here, by integrating phosphoproteomic data with human protein microarray-based AKT1 kinase assays, we discover and validate six novel AKT1 substrates, including cortactin. Through mutagenesis studies, we demonstrate that phosphorylation of cortactin by AKT1 is important for mutant PI3K-enhanced cell migration and invasion. Our study describes a quantitative and global approach for identifying mutation-speciﬁc signalling events and for discovering novel signalling molecules as readouts of pathway activation or potential therapeutic targets. 1 McKusick-Nathans Institute of Genetic Medicine and Department of Biological Chemistry, Johns Hopkins University School of Medicine, 733 North Broadway, BRB 527, Baltimore, Maryland 21205, USA.
[Show full text]
Supplementary Information
Osa et al Supplementary Information Clinical implications of monitoring nivolumab immunokinetics in previously treated non– small cell lung cancer patients Akio Osa, Takeshi Uenami, Shohei Koyama, Kosuke Fujimoto, Daisuke Okuzaki, Takayuki Takimoto, Haruhiko Hirata, Yukihiro Yano, Soichiro Yokota, Yuhei Kinehara, Yujiro Naito, Tomoyuki Otsuka, Masaki Kanazu, Muneyoshi Kuroyama, Masanari Hamaguchi, Taro Koba, Yu Futami, Mikako Ishijima, Yasuhiko Suga, Yuki Akazawa, Hirotomo Machiyama, Kota Iwahori, Hyota Takamatsu, Izumi Nagatomo, Yoshito Takeda, Hiroshi Kida, Esra A. Akbay, Peter S. Hammerman, Kwok-kin Wong, Glenn Dranoff, Masahide Mori, Takashi Kijima, Atsushi Kumanogoh Supplemental Figures 1 – 8 1 Osa et al Supplemental Figure 1. The frequency of nivolumab-bound T cells was maintained in patients who continued treatment. Nivolumab binding in CD8 and CD4 T cells was analyzed at two follow-up points, as indicated, in fresh peripheral blood from three representative cases from protocol 1 that continued treatment. 2 Osa et al Supplemental Figure 2. Long-term follow-up of nivolumab binding to T cells from fresh whole blood. Nivolumab binding was followed up in fresh peripheral blood from an additional case, Pt.7. 3 Osa et al Supplemental Figure 3. Long-term duration of nivolumab binding is due to sustained circulation of residual nivolumab in plasma. (A) PBMCs acquired from Pt.8 and 9 at pretreatment (pre PBMCs) and after a single dose (post 1 PBMCs) were cultured in regular medium without nivolumab (top and middle). Pre PBMCs were also incubated with 10 µg/ml nivolumab in vitro before the cultures were started (bottom). Nivolumab binding status was monitored at the indicated time points.
[Show full text]
Investigations on the Human Myt1 Kinase: Substrate Studies, Assay Development and Inhibitor Screening Alexander Rohe
Investigations on the Human Myt1 Kinase: Substrate Studies, Assay Development and Inhibitor Screening Dissertation zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) vorgelegt der Naturwissenschaftlichen Fakultät I - Biowissenschaften Martin-Luther-Universität Halle-Wittenberg von Alexander Rohe geboren am 06.11.1985 in Saarbrücken Gutachter: 1. Prof. Dr. W. Sippl 2. Prof. Dr. M. Schutkowski 3. Prof. Dr. M. Jung Halle (Saale), 28.August 2013 Tag der Verteidigung: 15. Januar 2014 II III Durchgeführt am Institut für Pharmazie, Abteilung Medizinische Chemie, Martin-Luther-Universität Halle-Wittenberg Gutachter: Prof. Dr. W. Sippl, Martin-Luther-Universität Halle-Wittenberg Zweitgutachter: Prof. Dr. M. Schutkowski, Martin-Luther-Universität Halle-Wittenberg Drittgutachter: Prof. Dr. M. Jung, Albert-Ludwigs-Universität Freiburg i. Br. IV Table of Contents V Table of Contents Table of Contents .................................................................................................... V Abbreviations and Symbols .................................................................................. IX List of Figures ...................................................................................................... XV List of Tables..................................................................................................... XVII 1. Introduction ...................................................................................................... 1 2. Theoretical Background ..................................................................................
[Show full text]
Brain-Restricted Mtor Inhibition with Binary Pharmacology 2 3 Ziyang Zhang1, Qiwen Fan2,3, Xujun Luo2,3, Kevin J
bioRxiv preprint doi: https://doi.org/10.1101/2020.10.12.336677; this version posted October 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Brain-Restricted mTOR Inhibition with Binary Pharmacology 2 3 Ziyang Zhang1, Qiwen Fan2,3, Xujun Luo2,3, Kevin J. Lou1, William A. Weiss2,3,4,5, Kevan 4 M. Shokat1,* 5 6 1 Department of Cellular and Molecular Pharmacology and Howard Hughes Medical 7 Institute, University of California, San Francisco, California 8 2 Helen Diller Family Comprehensive Cancer Center, San Francisco, California 9 3 Department of Neurology, University of California, San Francisco, California 10 4 Department of Pediatrics, University of California, San Francisco, California 11 5 Department of Neurological Surgery, University of California, San Francisco, California 12 * Corresponding author. [email protected] (K.M.S.). 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.10.12.336677; this version posted October 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 13 Abstract 14 On-target-off-tissue drug engagement is an important source of adverse effects 15 that constrains the therapeutic window of drug candidates. In diseases of the central 16 nervous system, drugs with brain-restricted pharmacology are highly desirable.
[Show full text]
Defining the KRAS-Regulated Kinome in KRAS-Mutant Pancreatic Cancer
bioRxiv preprint doi: https://doi.org/10.1101/2021.04.27.441678; this version posted April 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Submitted Manuscript: Confidential Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer J. Nathaniel Diehl1, Jennifer E. Klomp2, Kayla R. Snare2, Devon R. Blake3, Priya S. Hibshman2,4, Zane D. Kaiser2, Thomas S.K. Gilbert3,5, Elisa Baldelli6, Mariaelena Pierobon6, Björn Papke2, Runying Yang2, Richard G. Hodge2, Naim U. Rashid2,7, Emanuel F. Petricoin III6, Laura E. Herring3,5, Lee M. Graves2,3,5, Adrienne D. Cox2,3,4,8, Channing J. Der1,2,3,4* 1Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; 2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; 3Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; 4Cell Biology and Physiology Curriculum, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; 5UNC Michael Hooker Proteomics Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; 6Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia, USA; 7Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; 8Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. *Corresponding author: Email: [email protected] Running title: Defining the KRAS-regulated kinome 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.04.27.441678; this version posted April 30, 2021.
[Show full text]